Previous 10 | Next 10 |
Shares of Exact Sciences (NASDAQ: EXAS) were soaring 9.8% higher as of 3:38 p.m. EDT on Thursday. The company announced on Wednesday that new data for its Oncotype DX tests will be showcased at the upcoming American Society of Clinical Oncology (ASCO) annual meeting in June. However...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating virtually in the following investor conferences. William Blair 41 st Annual Growth Stock Conference Fireside Chat on Tuesday, June 1 st at 12:00 p....
Data from 20 abstracts demonstrate value of company’s blood tests across the continuum of cancer care, including: screening, therapy selection, residual and recurrent disease detection, and biopharmaceutical drug development Guardant Health, Inc. (Nasdaq: GH), to pres...
Cathie Wood has gained notoriety from making some seemingly outlandish calls on stocks and for being right. Her company's extrapolation of real world data and technological trends has proved to be an incredibly profitable investing strategy, even after some recent turbulence. One of her...
Image source: The Motley Fool. Guardant Health Inc (NASDAQ: GH) Q1 2021 Earnings Call May 6, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Guardant Health Inc (GH) Q1 2021 Earnings Call Transcript
Start Time: 16:30 End Time: 16:57 Guardant Health, Inc. (GH) Q1 2021 Earnings Conference Call May 06, 2021, 16:30 PM ET Company Participants Helmy Eltoukhy - CEO AmirAli Talasaz - President and COO Mike Bell - CFO Carrie Mendivil - IR Conference Call Participants Presentation Operator Thank y...
Achieved revenue of $78.7 million, driven by approximately 18,400 clinical tests Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analyt...
Guardant Health (GH) announces the appointment of Craig Eagle as the company’s new chief medical officer ((CMO)).Prior to joining Guardant Health, Eagle most recently served as Vice President of Medical Affairs Oncology for Genentech where he oversaw the medical pro...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announces the appointment of Craig Eagle, MD as the company’s new Chief Medical Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/hom...
Guardant Health ([[GH]] -1.0%) is trading marginally lower today as a recent SEC filing submitted by the company indicates that SoftBank Vision Fund a subsidiary of famed Japanese conglomerate Softbank Group has cut its investment in company shares.SoftBank Vision Fund which previously o...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...